Innovative immunotherapy shows promise against aggressive T cell cancers

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerate…

Universal CAR T cell therapy shows promise for aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.

Innovative immunotherapy shows promise against aggressive T cell cancers

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led by researchers at Washington University School of Medicine in St. Louis.

Dual-Targeted CAR T Cell Therapy Shows Promise in Slowing Aggressive Brain

In a groundbreaking leap forward for brain cancer treatment, researchers from the University of Pennsylvania have unveiled promising results from a novel dual-target CAR T cell therapy aimed at recurrent glioblastoma (GBM), one of the most aggressive and lethal brain tumors known to medicine. This innovative approach employs a personalized immunotherapy strategy that harnesses the patient’s own immune cells, genetically engineered to recognize a…

Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence

Autologous CAR-T therapy has shown promising outcomes in the treatment of tumors, particularly hematological malignancies over the past years. However…

Dual-target CAR T-cell therapy slows growth of aggressive brain cancer

Researchers from Penn Medicine have demonstrated encouraging tumor reductions rarely seen in recurrent glioblastoma following phase I clinical trials.